Abstract. Multiple myeloma (MM) is the second most common haematological malignancy and remains an incurable disease, with most patients relapsing and requiring further treatment. Augmenter of liver regeneration (ALR) is a vital protein affecting fundamental processes such as energy transduction, cell survival and regeneration. Silencing ALR inhibits cell proliferation and triggers apoptosis in human MM U266 cells. However, little is known about the role of 15-kDa-ALR on MM. In the present study, the role of 15-kDa-ALR in human MM cells was investigated. Blocking extracellular 15-kDa-ALR with an anti-ALR monoclonal antibody (McAb) decreased the proliferation and viability of U266 cells. However, the results of flow cytometry revealed no changes in apoptosis, and the expression levels of Bax, Bcl-2, caspase-3 and cleaved caspase-3 were not affected. However, combined treatment with anti-ALR McAb and epirubicin increased the apoptosis of U266 cells. RNA sequencing results indicated that the ERK1/2, JNK-MAPK and STAT3 signaling pathways, as well as the cell cycle, were associated with the mechanism of action of the anti-ALR McAb, and PCR, western blotting and cell cycle analysis confirmed these results. The present findings suggested that blocking extracellular 15-kDa-ALR in U266 cells with an anti-ALR McAb decreased cell proliferation via the MAPK, STAT3 and cell cycle signaling pathways without increasing apoptosis. Thus, 15-kDa-ALR may be a new therapeutic target for myeloma.

Introduction

Multiple myeloma (MM) accounts for ~13% of hematological cancers, with an estimated 24,280 to 30,330 new cases and 12,650 deaths in 2016 (1), and patients survive an average of 3 years (2). Although modern combination therapies induce rapid, deep and sustainable responses, as well as prolonging survival (3), MM remains an incurable disease, and the majority of patients relapses and requires further treatment (4). Thus, novel targets for treating MM are urgently required.

Augmenter of liver regeneration (ALR), also known as GFER, is a vital protein in various biological processes that was first identified by Hagiya et al (5). ALR occurs in two isoforms: A long form comprising 205 amino acid residues with a molecular weight of 23 kDa (6) that is present in the intermembrane space of mitochondria (7), and a short form consisting of 125 amino acids with a molecular weight of 15 kDa (8) that is secreted by hepatocytes and is present in serum (9). Accumulating evidence has revealed that ALR affects fundamental processes such as energy transduction, cell survival, cell regeneration (11), metabolic homeostasis, iron metabolism (12) and stem cell maintenance (13). Different isoforms of ALR have been associated with different subcellular locations and therefore specific functions (14), but despite considerable research on the overexpression and inhibition of 23- and 15-kDa-ALR, their specific functions remain unclear.

A previous study has demonstrated that silencing ALR can influence proliferation and apoptosis in human MM U266 cells (15). However, little is known about the role of 15-kDa-ALR in MM. Therefore, the present study aimed to investigate the role and mechanism of extracellular 15-kDa-ALR in MM.
Materials and methods

Preparation of anti-ALR monoclonal antibody. The 15-kDa-recombinant human ALR (rhALR) protein was purchased from Abcam. A total of 5 female BALB/c mice (age, 6-10 weeks old; weight, 20-25 g) were obtained from the Experimental Animal Center of Chongqing Medical University (Chongqing, China). All mice received humane treatment according to the regulations of the Institutional Animal Care and Use Committee of Chongqing Medical University. All mice were housed in a specific pathogen-free laboratory in an acclimatized room at standard room conditions (25±2°C and 55% humidity), with a 12-h light/dark cycle. Mice were allowed free access to water and standard chow. The rhALR protein was injected subcutaneously into five BALB/c mice for immunization. Subsequently, anti-ALR monoclonal antibody (McAb) was prepared using hybridoma technology as previously described (16). Splenocytes were harvested and fused with myeloma SP2/0 cells (obtained from the Institute of Viral Hepatitis of Chongqing Medical University) to generate hybridoma cells, which were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 20% FBS (HyClone; Cytiva) and 100 U/ml penicillin and streptomycin at 37°C in a humidified atmosphere with 5% CO₂. Single antibody-producing hybridoma cells were isolated using the limiting dilution technique, and supernatants of growth-positive wells were aspirated and screened for the presence of antibodies using ELISA. The ratio of the absorbance of hybridoma cell culture supernatants and myeloma cell SP2/0 culture supernatants was measured at 450 nm. Absorbance >1.5 at optical density (OD)450 nm and ratio of the absorbance of hybridoma cell culture supernatants to that of negative controls >2.1 were considered positive. Single McAb-producing hybridoma cells were isolated and were injected intraperitoneally into ten BALB/c mice to produce ascites for large-scale McAb production. All mice were anesthetized using 3% isoflurane and sacrificed by cervical dislocation 10-14 days after injection. Ascitic fluid containing McAb was harvested from the intraperitoneal cavity using a 21-G needle and centrifuged at 10,000 x g at 4°C for 10 min. Isotypes of McAb were detected using IsoQuick strips (Roche Molecular Diagnostics). Cells were washed twice with cold PBS and resuspended in 1X binding buffer at a cell density of 1x10⁶ cells/ml. Cells were incubated with 5 µl FITC and 10 µl PI for 15 min at room temperature in the dark. A cytometer (BD Biosciences) was used to calculate cell viability: Cell viability (%) = [A (ascites) - A (blank)] / [A (0 dosing) - A (blank)] x 100.

ELISA. For ELISA, 96-well plates were coated with 15-kDa-rhALR (4 µg/ml) in 100 µl coating buffer overnight at 4°C and incubated with blocking solution, consisting of 3% BSA (Beijing Solarbio Science & Technology Co., Ltd.) in 0.05% Tween-20-PBS (PBST) solution, at 4°C overnight. Ascites were diluted at the ratio of 1:100, 1:1,000, 1:10,000, 1:100,000 and 1:1,000,000. After washing with PBST, 100 µl ascites diluted at different ratios were added and incubated at 4°C overnight. After incubation, the plates were washed three times with PBST, and 100 µl 1:10,000-diluted HRP-conjugated goat anti-mouse immunoglobulin (cat. no. 7076P2; Cell Signaling Technology, Inc.) was added to each well and incubated for 1 h at room temperature. After washing three times with PBST, the enzymatic activity was determined by adding 100 µl 3,3',5,5'-tetramethylbenzidine substrate solution and incubating in the dark at 37°C for 30 min, followed by adding 5 µl 2M sulfuric acid per well to terminate the reaction. The absorbance was recorded at 450 nm using a microplate reader.

Cell culture and treatment. The human MM U266, RPMI8226 and MML.S cell lines were obtained from the Institute of Viral Hepatitis of Chongqing Medical University. U266 and MM1.S cells were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (HyClone; Cytiva) and 100 U/ml penicillin and streptomycin (Invitrogen; Thermo Fisher Scientific, Inc.). RPMI8226 cells were cultured in Iscove's modified Dulbecco's medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 20% FBS and 100 U/ml penicillin and streptomycin. Cells were grown at 37°C in a humidified atmosphere with 5% CO₂. Ascites containing anti-ALR McAb were added to the medium as the treatment group, while ascites produced by negative hybridoma cells constituted the negative control group, and PBS was used for the blank group.

Cell viability assay. Different dilutions of ascites containing anti-ALR McAb (1:10, 1:50 and 1:100), negative ascites and PBS were incubated with U266 cells for different time periods (24, 48 and 72 h). A Cell Counting Kit-8 (CCK-8; Beijing Solarbio Science & Technology Co., Ltd.) assay was used to determine the cell survival rate according to the manufacturer's protocol. Cells were plated in 96-well plates at a density of 1x10⁵ cells/well. After culturing at 37°C for 24, 48 or 72 h, the quantity of viable cells was measured. A total of 10 µl CCK-8 reagent was added to each well and incubated at 37°C for 2 h. The absorbance was recorded at 450 nm using a microplate reader, and the following formula was used to calculate cell viability: Cell viability (%) = [A (ascites) - A (blank)] / [A (0 dosing) - A (blank)] x 100.

Apoptosis analysis via flow cytometry. The apoptosis rates of human MM cells treated with anti-ALR McAb, negative ascites and PBS were determined using an Annexin V-FITC/PI staining kit (BD Biosciences). Cells were washed twice with cold PBS and resuspended in 1X binding buffer at a cell density of 1x10⁶ cells/ml. Cells were incubated with 5 µl FITC and 10 µl PI for 15 min at room temperature in the dark. A total of 1x10⁴ cells were recorded by the FACSCanto II flow cytometer (BD Biosciences) for each sample. Fluorescence data were measured and analysed using FACSDjango II software (BD Biosciences). Apoptosis detection in the presence of injury factors was the same as aforementioned. Ascites containing anti-ALR McAb, negative ascites and PBS were incubated with U266 cells at the concentration of 1:10 for 48 h. Subsequently, 0.004 mg/ml epirubicin (Pfizer, Inc.) was added to the medium for 24 h at 37°C. Cells were harvested for apoptosis analysis. A cell cycle and apoptosis analysis kit
(Beijing Solarbio Science & Technology Co., Ltd.) was used to determine the cell cycle according to the manufacturer's protocol. U266 cells were treated with anti-ALR McAb, negative ascites and PBS at a concentration of 1:10. After culturing at 37°C for 72 h, cells were harvested and washed with PBS, then fixed with 70% ethanol at 4°C for 2 h. A total of 100 µl RNase A was added for 30 min at 37°C, then PI (0.5 ml) was added and incubated for 10 min at 4°C in the dark for staining. Next, cells were assessed using a FACScanto II flow cytometer (BD Biosciences). Cell cycle was analyzed using ModFit LT software (version 3.2; Verity Software House, Inc.).

**Western blotting.** Proteins were extracted from cells using RIPA lysis buffer (Beyotime Institute of Biotechnology) and quantified using a BCA kit (Beyotime Institute of Biotechnology). Proteins (60 µg/lane) were separated via 15% SDS-PAGE, transferred to polyvinylidene fluoride membranes, blocked with 5% skimmed milk in TBS for 1 h at 37°C and then incubated overnight at 4°C with primary antibodies. The primary antibodies and dilutions used were as follows: Anti-Bax (1:1,000; cat. no. 2774S), anti-Bcl-2 (1:1,000; cat. no. 4223T), anti-caspase-3 (1:1,000; cat. no. 9662S), anti-cleaved caspase-3 (1:1,000; cat. no. 9661T), anti-p44/42 (1:1,000; cat. no. 4695T), anti-phospho-p44/42 (1:1,000; cat. no. 4377T), anti-p38 (1:1,000; cat. no. 8690T), anti-phospho-p38 (1:1,000; cat. no. 4511T), anti-JNK (1:1,000; cat. no. 9252T), anti-phospho-JNK (1:1,000; cat. no. 9251S), anti-STAT3 (1:1,000; cat. no. 4312T), anti-phospho-STAT3 (1:1,000; cat. no. 9145T) and anti-β-actin (1:1,000; cat. no. 4970T), all from Cell Signaling Technology, Inc. Anti-β-tubulin (1:1,000; cat. no. 102053-T34) was purchased from Sino Biological, Inc. Anti-CDK1 (1:1,000; cat. no. ab201008) and anti-cyclin D1 (1:1,000; cat. no. ab40754) were obtained from Abcam. After incubation for 1 h at 37°C with HRP-conjugated secondary antibodies (1:10,000; cat. no. 7074P2; Cell Signaling Technology, Inc.), the protein bands were visualized using an enhanced chemiluminescence kit (Nanjing KeyGen Biotech Technology, Inc.), the protein bands were visualized using an ChemiDoc Connect Real-Time System (Bio‑Rad Laboratories, Inc.). Densitometry was analyzed using Image lab™ V3.0 software (Bio‑Rad Laboratories, Inc.).

**EdU assay.** Cell proliferation was measured using an EdU assay kit (Guangzhou RiboBio Co., Ltd.) according to the manufacturer’s protocol. U266 cells were cultured at a density of 1x10⁵ cells/well in 6-well plates and treated with 1:10 concentration of anti-ALR McAb ascites, negative ascites or PBS at 37°C for 72 h. A total of 50 µM EdU was added to the medium and incubated for 4 h at 37°C. Cells were harvested and fixed with 4% formaldehyde for 15 min at room temperature, centrifuged at 600 x g for 10 min at room temperature, and washed with PBS. Subsequently, 2 mg/l glycine solution was used to neutralise the response, and 0.5% Triton X-100 was added and incubated for 10 min at room temperature for permeabilisation. The supernatant was discarded after centrifugation (600 x g for 10 min at room temperature), and cells were washed again with PBS and treated with 1X Apollo reaction cocktail (100 µl/well; Guangzhou RiboBio Co., Ltd.) in the dark for 10 min at room temperature. Cells were washed three times with 0.5% Triton X-100 and resuspended in 500 µl PBS. Next, 1x10⁴ cells from each sample were assessed using a FACScanto II flow cytometer (BD Biosciences). Fluorescence data were measured and analysed using FACScanto II software (BD Biosciences).

**RNA preparation, library construction and RNA sequencing (RNA-seq).** Total RNA was extracted from U266 cells (n=3; treatment and control groups) using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.). RNA quality was checked using a Bioanalyzer 2100 instrument (Agilent Technologies, Inc.), and cDNA libraries were constructed for each pooled RNA sample using a NEBNext Ultra Directional RNA Library Prep Kit (Illumina, Inc.) according to the manufacturer's protocol. Tagged cDNA libraries were pooled in equal ratios and used for 150-bp paired-end sequencing in a single lane of an Illumina HiSeqX Ten instrument (Illumina, Inc.).

**Differentially expressed genes and bioinformatics analysis.** The DESeq algorithm (17) was applied to filter differentially expressed genes. The results were filtered based on fold-change (FC) and false discovery rate (FDR) using the following criteria: log2FC > 0.585 or < -0.585, and FDR < 0.05. Volcano plots were drawn using the R software package (ggplot2; version 3.2.1; https://ggplot2.tidyverse.org/) based on the analysis of differentially expressed genes, and colour was determined by the filtering criteria. Gene Ontology (GO) analysis was performed to predict the biological functions of differentially expressed genes. GO annotations were downloaded from the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/), UniProt (http://www.uniprot.org/) and GO (http://www.geneontology.org/) databases. Fisher's exact tests were used to identify significant GO categories, and FDR was used to correct the P-values. FDR < 0.05 was considered to indicate a statistically significant difference. Pathway analysis was used to identify significant pathways associated with the differentially expressed genes according to the Kyoto Encyclopedia of Genes and Genomes database (https://www.kegg.jp/). Fisher's exact tests were used to select significant pathways, and the threshold of significance was defined by the P-value and FDR < 0.05. Protein-protein interaction (PPI) network analysis of differentially expressed genes was performed using the online Search Tool for the Retrieval of Interacting Genes/Proteins (version 11.0; https://string-db.org/) (18). The top 10 hub genes were identified using the cytoHubba plugin app of Cytoscape software (version 3.7.2) (19). Path-Act-Network (https://www.kegg.jp/kegg/pathway.html) was employed to select genes in enriched biological pathways, and Cytoscape was used for the graphical representation of pathways.

**Reverse transcription-quantitative PCR (RT-qPCR).** Total RNA was extracted from U266 cells using a Total RNA Extraction kit (BioTeke Corporation) according to the manufacturer's protocol. Total RNA was reverse transcribed to cDNA using a PrimeScript II Reverse Transcriptase kit (Takara Bio, Inc.) according to the manufacturer’s protocol. RT-qPCR was performed using SYBR Premix (Takara Bio, Inc.). For quantitative analysis, hub genes, along with GAPDH as a positive control, were amplified using SYBR Premix on a CFX Connect Real-Time System (Bio-Rad Laboratories, Inc.). The
qPCR thermocycling conditions were as follows: One cycle at 94˚C for 30 sec, followed by 40 cycles of 5 sec at 94˚C for denaturation and 60˚C for 30 sec for annealing/extension using the two-step method. Relative gene expression levels were calculated using CFX Manager software (version 3.0; Bio-Rad Laboratories, Inc). The 2^ΔΔCq method was used to evaluate the mRNA expression (20). Primer sequences are shown in Table I.

Statistical analysis. Each experiment was performed three times separately. All quantitative data are expressed as the mean ± standard deviation calculated using GraphPad Prism 5.0 software (GraphPad Software, Inc.). One-way ANOVA followed by Tukey’s post hoc test was used to analyse differences among multiple groups. P<0.05 was considered to indicate a statistically significant difference.

Results

Anti-ALR McAb verification and ALR expression in MM cell lines. One desirable and stable clone was screened via the limiting dilution technique. Isotypes of McAb were IgM detected using IsoQuick strips. ELISA was performed to test the ability of anti-ALR McAb to bind 15-kDa-rhALR, with a control group comprising ascites from the negative hybridoma. Absorbance >1.5 at OD450 nm and ratio of the absorbance of anti-ALR ascites to that of negative ascites >2.1 were considered to indicate specific binding of antigen and antibody. As shown in Fig. 1A, the absorbance values in the anti-ALR(+) ascites and negative ascites ranging from 1:100 to 1:1,000,000 were 2.17±0.10 vs. 1.18±0.02, 2.30±0.16 vs. 0.88±0.14, 2.20±0.36 vs. 0.49±0.01, 1.90±0.52 vs. 0.28±0.09, 0.56±0.12 vs. 0.19±0.04 at dilutions ranging from 1:100 to 1:1,000,000, respectively. The results suggested that the antibody titer in anti-ALR McAb ascites was 10^5. The absorbance values of negative ascites was <1.5, and as the dilution of negative ascites increased from 1:100 to 1:10^6, the absorbance values decreased rapidly, which suggested that there was a non-specific binding of negative ascites to rhALR protein. However, after purification, the absorbance <1.5 at OD450 nm suggested that the titer of the antibody was markedly decreased, and therefore the purified antibody was not suitable for subsequent experiments. ELISA was used to quantify 15-kDa-ALR in the cell medium, and the concentration of 15-kDa-ALR in the medium in MM1.S, RPMI8226 and U266 cells was 152.7±21.43, 200.7±31.56 and 179.5±68.92 ng/ml, respectively (data not shown), suggesting that there were no differences in the quantity of ALR in the medium. Anti-ALR McAb ascites were diluted to 1:10,000 as the primary antibody for western blotting, and anti-ALR McAb was found to bind specifically to 15-kDa-rhALR (Fig. 1B).
Effect of blocking 15-kDa-ALR on cell survival and proliferation.
To construct a cell model, U266 cells were treated with different McAb concentrations (1:100, 1:50 and 1:10 ratio of ascites to medium) for different durations (24, 48 and 72 h). The CCK-8 assay results revealed that, when treated at 1:100 and 1:50 dilutions for 24 h, cell viability increased slightly, and then decreased after 48 and 72 h. The higher the concentration, the lower the cell viability when cells were treated for 48 and 72 h. At a 1:10 concentration, cell viability decreased in a time-dependent manner, and cell viability was significantly lower than that at the other two concentrations at 24 h (96.43±5.78, 101.11±4.79 and 100.44±2.60% at 1:10, 1:50 and 1:100, respectively; \( P<0.05 \)), 48 h (72.62±3.35, 82.95±3.98 and 86.31±3.59% at 1:10, 1:50 and 1:100, respectively; \( P<0.01 \)) and 72 h (49.97±3.31, 65.72±2.26 and 74.93±2.55% at 1:10, 1:50 and 1:100, respectively; \( P<0.01 \)) (Fig. 2A). Therefore, a concentration of 1:10 was selected for subsequent experiments.

Next, cell viability was compared among the anti-ALR treatment, negative ascites and PBS groups. The results revealed that PBS had no influence on cell viability at a concentration of 1:10, regardless of treatment duration. Cell viability increased slightly in the negative ascites group at a concentration of 1:10 for 72 h compared with 48 h, and there was a significant difference between the negative ascites and PBS groups (\( P<0.05 \); Fig. 2B). The effect of the anti-ALR McAb on survival rate at 48 and 72 h was significantly lower than that in the other two groups (\( P<0.001 \); Fig. 2B). Thus, an anti-ALR McAb concentration of 1:10 for 72 h was selected for subsequent experiments, with the same concentration of negative ascites as the control and PBS blank groups.

Cell proliferation was measured using EdU assay, and treatment with anti-ALR McAb, negative ascites and PBS yielded U266 cell proliferation rates of 23.77±1.39, 37.17±1.93 and 36.33±0.55, respectively (\( P<0.01 \); Fig. 2C).

Effect of blocking 15-kDa-ALR on apoptosis. Since the anti-apoptotic effect of exogenous ALR in the liver has been demonstrated in various injury models (21,22), apoptosis in U266 cells was investigated via flow cytometry and western blotting (Fig. 3). When treated with McAb for 72 h, the proportion of apoptotic cells (both late and early apoptotic cells) detected by flow cytometry did not differ between the three groups (7.70±0.29, 10.91±3.79 and 7.11±0.74% for the McAb, negative ascites and PBS groups, respectively; Fig. 3A). Additionally, the expression levels of the pro-apoptotic protein Bax and the anti-apoptotic protein Bcl-2 were measured, and there was no difference in the ratio of the two proteins between the three groups (\( P>0.05 \); Fig. 3B). Similarly, there were no differences in caspase-3 expression and in the ratio of cleaved caspase-3/caspase-3 (\( P>0.05 \); Fig. 3B). However, following cell injury induced by 0.004 mg/ml epirubicin treatment for 24 h, the proportion of apoptotic cells was significantly increased after blocking extracellular ALR with McAb (\( P<0.05 \); Fig. 3C).

Differentially expressed genes. To clarify how extracellular ALR affected U266 MM cells, RNA-Seq was performed to identify differentially expressed RNAs between the anti-ALR McAb and negative ascites groups. A total of 20,030 genes were subjected to differential gene analysis after filtering low-abundance genes, and the results revealed 289 and 138 significantly upregulated and downregulated genes, respectively. Hierarchical cluster analysis confirmed the quality of the microarray data and the differences between the treatment and control groups (Fig. 4A). The distribution of RNAs is shown in a volcano plot (Fig. 4B).
Figure 3. Apoptosis of U266 cells treated with anti-ALR McAb, negative ascites or PBS. (A) Flow cytometry analysis of the apoptosis of U266 cells treated with anti-ALR McAb, negative ascites or PBS at a concentration of 1:10 for 72 h, followed by Annexin V-FITC/PI staining. (B) Analysis of apoptosis-associated protein expression by western blotting. U266 cells were harvested to examine the expression levels of Bax, Bcl-2, caspase-3 and cleaved caspase-3 after treatment with anti-ALR McAb, negative ascites or PBS at a concentration of 1:10 for 72 h. (C) U266 cells treated with anti-ALR McAb, negative ascites or PBS at a concentration of 1:10 for 48 h were co-treated with epirubicin at 0.004 mg/ml for 24 h, and apoptosis was examined by flow cytometry after Annexin V-FITC/PI staining. *P<0.05 anti-ALR McAb group vs. negative ascites and PBS groups. McAb, monoclonal antibody; ALR, augmenter of liver regeneration.

Figure 4. Differentially expressed genes between the anti-ALR McAb and negative control groups, as assessed by RNA-sequencing. (A) Heat map analysis of differentially expressed genes in U266 cells treated with anti-ALR McAb (trt) or negative ascites (con). Red indicates genes with higher expression, green indicates genes with lower expression and black indicates genes not differing in terms of their expression levels between the two groups. (B) Volcano plots showing the number, significance and reliability of differentially expressed genes between the two groups. Red dots indicate upregulation, while blue dots indicate downregulation. McAb, monoclonal antibody; ALR, augmenter of liver regeneration; FDR, false discovery rate; FC, fold-change; trt, treatment group; con, control group.
GO, pathway enrichment, Path-Act-Network and PPI network analyses, and hub gene validation. GO analysis revealed that differential genes in the biological process category were primarily associated with ‘mitotic nuclear division’, ‘cell cycle’ and ‘cell division’, while those in the molecular function category were associated with ‘nucleic acid binding’, ‘DNA binding’ and ‘RNA polymerase II core promoter proximal region sequence-specific DNA binding’; the cellular component category was primarily enriched in terms associated with ‘nucleus’, ‘centrosome’ and ‘intracellular’ functions (Fig. 5A). GO enrichment analysis revealed that these differential genes were mainly associated with ‘cell cycle’, ‘cell division’, ‘mitotic nuclear division’ and ‘mitotic cell cycle’ (Fig. 5B), all of which are associated with cell proliferation.

Pathway analysis based on gene annotation databases can identify pathways in which differentially expressed genes are significantly enriched, and pathways can directly reflect the effects of genes on phenotypes (23). In the present study, 12 signaling pathways were significantly different between groups (Fig. 6A), and the top three pathways were ‘pyrimidine metabolism’, ‘Fanconi anemia pathway’ and ‘oocyte meiosis’ (Fig. 6B).

The PPI network based on the identified differentially expressed genes is shown in Fig. 7A. The top 10 genes were CDK1, SMC3, KIF11, SMC4, NDC80, NACAPG, TTK, CENPE, NUF2 and CENPU, all of which are potential hub genes according to the scores generated by the cytoHubba plugin app (Fig. 7B). Path-Act-Network analysis was used to probe signal transmission and regulation processes among the various signaling pathways, and MAPK, cell cycle and JAK-STAT were identified as the key signaling pathways (Fig. 7C).

Hub gene and pathway validation. The top 10 hub genes were validated via RT-qPCR, and the results are shown in Fig. 8. The relative mRNA expression levels of CDK1 were downregulated, while those of the other nine hub genes were upregulated in the anti-ALR McAb group compared with in
the negative ascites and PBS groups. The changes in hub genes were consistent with the microarray results. However, the changes in TTK and CENPU were not statistically significant.

Signaling pathways were verified via western blotting. The MAPK pathway includes the p44/42, p38 and JNK cascades (24). The protein expression levels of p44/42 were downregulated in the anti-ALR McAb treatment group compared with in the negative ascites and PBS groups, while p38 and phospho-p38 exhibited no significant difference in expression. JNK expression was significantly downregulated, while phospho-JNK expression was significantly upregulated in the anti-ALR McAb group compared with in the negative ascites and PBS groups (Fig. 9A). Additionally, STAT3 expression was significantly downregulated, as well as that of CDK1 and cyclin D1 (Fig. 9B). Cell cycle analysis revealed cell cycle arrest at the S phase in the anti-ALR McAb group, but not in the PBS or negative control groups (Fig. 9D).

Discussion

ALR mRNA expression has been previously detected in several tissues, being relatively high in liver, kidney, testis and brain (5,25). Additionally, ALR has been found in the serum in both rat bacterial sepsis and mouse hemorrhagic shock models (21). ALR expression is upregulated in a number of solid tumours, such as hepatocellular carcinoma (22,26), colon cancer (27) and T-cell leukaemia (28), and overexpression of ALR has a protective effect on these tumour cells. Furthermore, a protective effect of ALR was observed in neuroblastoma (29) and glioma (30). Our previous study revealed that ALR expression was higher in U266 MM cells than in human peripheral blood mononuclear cells (15). Our research group has detected 15-kDa-ALR in patients with MM (unpublished data). In small samples of bone marrow, the expression levels of 15-kDa-ALR in myeloma cells were higher than those in healthy volunteers (unpublished data). However, the sample size was too small for statistical analysis, and it was difficult to obtain bone marrow samples just for this experiment, so the data was unpublished. In the present study, U266 cells exhibited the highest expression levels of 15-kDa-ALR among the three cell lines evaluated and the best response to the 15-kDa-ALR McAb.

A McAb was used to block 15-kDa-ALR, which is secreted from cells, and can therefore avoid the influence of 23-kDa-ALR (9). In present study, an IgM purification column was used to perform IgM purification. However, after purification, the absorbance value of the purified antibody was <1.5 at OD450 nm. The results suggested that the purified antibody was not suitable for subsequent experiments. The ascites containing McAb were selected for subsequent experiments. The cell viability was increased in the negative ascites group compared with in the anti-ALR McAb group at a concentration of 1:10 after 72 h, and the difference between the negative ascites and PBS groups was statistically significant. It was speculated that the reason for this may be that negative ascites are rich in albumin and other factors, but not in anti-ALR McAb, which may provide nutrition to cells without being...
inhibited by anti-ALR McAb, which increased cell viability in the negative ascites group. Previous research demonstrated that exogenous ALR can induce proliferation in hepatocytes (33), and decrease apoptosis in liver cells (32,34), kidney cells (35,36) and lymphocytes (37). In order to verify whether 15-kDa-ALR had the same effect in U266 MM cells, EdU assays were used to assess cell proliferation. Treatment with the 15-kDa-ALR McAb decreased the cell proliferation rate compared with that of the control group, which was consistent with the effect of exogenous ALR on hepatocytes (38). The current results of CCK-8 and EdU assays demonstrated that 15-kDa-ALR secreted by U266 cells induced cell proliferation and that when autocrine ALR was blocked, cell proliferation decreased.

Figure 7. PPI network and Path-Act-Network analyses. (A) The online Search Tool for the Retrieval of Interacting Genes/Proteins (version 11.0) was used to construct the PPI network. Each node represents all proteins produced by a single protein-coding gene locus. Coloured nodes represent differentially expressed genes and the first shell of interactors. Edges represent protein-protein associations. (B) Top 10 hub genes identified using the cytoHubba plugin app of Cytoscape using the degree calculation method. The redder the node color, the higher the ranking. (C) Path-Act-Network analysis showing the upstream and downstream associations of significant signaling pathways. Red represents pathways that are significant only for upregulated genes, while green represents pathways that are significant only for downregulated genes. PPI, protein-protein interaction.

The anti-apoptotic effect of exogenous ALR has been demonstrated in different liver and kidney injury models (34,35). Exogenous ALR decreases caspase-3 activity, which may be due to decreased Bax expression (39). Furthermore, a previous study revealed that exogenous ALR decreases cell damage after partial hepatectomy by inducing anti-apoptotic Bcl-2 expression, suggesting that exogenous ALR enhances liver regeneration through apoptosis attenuation (34). Based on these findings, the present study hypothesized that apoptosis would increase if extracellular 15-kDa-ALR was blocked using a McAb. However, when U266 cells were treated with the McAb, apoptosis did not increase as expected. The flow cytometry results revealed that there was no difference in apoptosis, and western blotting indicated no differences in
the expression levels of Bax, Bcl-2 or caspase-3. Thus, the Bax/Bcl-2 ratio did not differ. The flow cytometry and western blotting results on apoptosis were inconsistent with previous research (32). This may be due to the fact that, in the present study, there were no injury factors such as TNFα, lipopolysaccharide or ischemia reperfusion, which may cause apoptosis; hence, blocking extracellular 15-kDa-ALR with antibodies alone may not be sufficient to stimulate apoptosis. However, a previous study revealed that silencing ALR triggered apoptosis in U266 cells without injury factors (15). Small hairpin RNA was used for silencing ALR expression in a previous study (15), which influenced 23- and 15-kDa-ALR at the same time. The 23-kDa-ALR is located in mitochondria and is involved in the process of oxidative phosphorylation, which is essential for life. When 23-kDa-ALR is silenced, apoptosis is triggered (38). In the present study, McAb blocked extracellular 15-kDa-ALR without influencing 23-kDa-ALR, which may be the reason for the inconsistent results with previous studies. Therefore, epirubicin, a traditional chemotherapy drug used to induce apoptosis (40), was employed in the present study. When the injury factor was present, apoptosis was increased as expected. These results confirmed that extracellular 15-kDa-ALR promoted proliferation in the absence of external injury factors, and the anti-apoptotic effect also occurred in the presence of injury factors.

A previous study demonstrated that the mechanisms of exogenous ALR affect the liver and that the MAPK signaling pathway is important in cell proliferation (14). In the present study, 15-kDa-ALR in the medium of U266 cells was detected by ELISA, which suggested that U266 cells may secrete 15-kDa-ALR. In the early research of our group, MTS assay was used to evaluate the influence of exogenous ALR on the proliferation of U266 cells, and the results suggested that after treating with exogenous ALR, the proliferation of U266 cells was significantly increased (unpublished data); however, the signal transduction mechanism in U266 cells was unclear. The use of an antibody to block extracellular 15-kDa-ALR in the present study was part of a research project on the signal transduction mechanism of 15-kDa-ALR in U266 cells. GO and pathway analysis of RNA-seq revealed that 15-kDa-ALR affected U266 cells via the MAPK signaling pathway, similar to the findings in hepatocytes (41). The MAPK signaling pathway involves ERKs, JNKs and p38-MAPKs. In the present study, western blotting indicated that the expression levels of p44/42 were downregulated in the treatment group. p44/42 can be activated by a variety of factors, such as inflammation (42) and heart failure (43), and this may be coincident with the activation of other pathways that promote contradictory biological responses (44). Combining the Path-Act-Network analysis and western blotting results demonstrated that p44/42 in the MAPK signaling pathway was downregulated by blocking extracellular 15-kDa-ALR and decreasing the proliferation of U266 cells. The expression levels of JNK and phospho-JNK were also altered in the present study, demonstrating that the JNK signaling pathway may be involved in the mechanism of blocking ALR in U266 cells. A recent study revealed that xanthohumol exhibits anti-myeloma activity via an ERK- and JNK-dependent mechanism in RPMI8226 cells (45). Similar to the aforementioned study, the present results indicated that the ERK1/2 and JNK signaling pathways may serve a role in anti-myeloma effects, but changes in protein expression depended on different stimuli. The expression levels of p38 and phospho-p38 were not significantly altered among the three groups; hence, the p38 signaling pathway may not be involved in the mechanisms of blocking 15-kDa-ALR. In MM cells, when the activity of the STAT3 signaling pathway was inhibited, cyclin D1 expression was downregulated, which inhibited the proliferation of myeloma cells and induced apoptosis (46). In the present study, STAT3 and cyclin D1 expression was attenuated by blocking extracellular 15-kDa-ALR, consistent with the results of a previous study (47), suggesting that the STAT3 signaling pathway may serve an important role in MM cells. However, STAT3 is attenuated by exogenous ALR (47), which contradicts the current findings, possibly due to the lack of injury factors in the present study.

According to the PPI network, the top 10 hub genes were associated with the cell cycle. In the current study, CDK1 expression was downregulated at both the mRNA and protein levels, and cell cycle analysis indicated that blocking 15-kDa-ALR caused cell cycle arrest in the S phase. A previous study on hematopoietic stem cells demonstrated that binding of ALR to JAB1 blocks JAB1 interaction with p27kip1, which promotes cell cycle arrest (48). Another study on leukemia suggested that changes in the MAPK signaling pathway may lead to S-phase cell cycle arrest (49). The mechanism of the cell cycle arrest induced by blocking 15-kDa-ALR may involve the combined effects of blocking the binding of ALR to JAB1 and the regulation of the MAPK signaling pathway induced by the anti-ALR McAb. The other hub genes identified in the present study included members of the centromere protein family (CENPE and CENPU), the nuclear division cycle 80 family (NDC80 and NUF2) and the SMC family.
(SMC3, SMC4 and NCAPG), all of which are associated with chromosome changes in the cell cycle. The expression levels of these genes were upregulated following anti-ALR treatment, which may be due to the fact that the cell cycle was arrested in S phase, inducing the upregulation of these genes when blocking 15-kDa-ALR.

In conclusion, the current results provided evidence that blocking extracellular 15-kDa-ALR inhibited the proliferation
of U266 MM cells through cell cycle arrest without increasing apoptosis in the absence of injury factors. The ERK1/2 and JNK branches of the MAPK signaling pathway, STAT3 signaling pathway and the cell cycle appeared to be involved in the possible mechanism (Fig. 10). Thus, 15-kDa-ALR may be a novel target for myeloma treatment.

Acknowledgements

The authors would like to thank Mrs. Wanyan Deng and Mr. Fang Jia (The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China) for their assistance in analysing the data and formatting the manuscript.

Funding

The present study was supported by a grant from the National Natural Science Foundation of China (grant no. 81871608).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

WH contributed to the conceptualization and investigation of the study, data curation and writing of the original draft. HS contributed to the conceptualization of the study, funding acquisition and review and editing of the manuscript. TH contributed to the analysis of experimental data. DZ, XL and HG performed the experiments. QL contributed to the conception of the study, data curation and writing of the original draft. WH contributed to the conceptualization and supervision of the study. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All experimental procedures involving animals were approved by the Animal Ethics and Use Committee of the Second Affiliated Hospital of Chongqing Medical University (Chongqing, China).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Kazandjian D: Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol 43: 676-681, 2016.
2. Kristinsson SY, Anderson WF and Landgren O: Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia 28: 1346-1348, 2014.
3. Landgren O and Iskander K: Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol 43: 676-681, 2016.
4. Sonneveld P and Brod MH: Clonal expansion and clonal diversity in relapsed/refractory myeloma. Haematologica 101: 396-406, 2016.
5. Hagiya M, Francavilla A, Polimeni L, Ihara I, Sakai H, Seki T, Shimonishi M, Porter KA and Starzl TE: Cloning and sequence analysis of the rat augmenter of liver regeneration (ALR) gene: Expression of biologically active recombinant ALR and demonstration of tissue distribution. Proc Natl Acad Sci USA 91: 8142-8146, 1994.
6. Li J, Xu WX, Zhan YQ, Cui XL, Cai WM, He FC and Yang XM: Identification and characterization of a novel isoform of hepatopoietin. World J Gastroenterol 8: 353-356, 2002.
7. Hofhaus G, Lee JE, Tews I, Rosenberg B and Lisowsky T: The N-terminal cysteine pair of yeast sulphhydroxyl oxidase Ervlp is essential for in vivo activity and interacts with the primary redox centre. Eur J Biochem 270: 1528-1535, 2003.
8. Cheng J, Zhong YW, Liu Y, Dong J, Yang JZ and Chen JM: Cloning and sequence analysis of human genomic DNA of augmenter of liver regeneration. World J Gastroenterol 6: 275-277, 2000.
9. Gandhi CR, Kuddus R, Subbotin VM, Prelich J, Murase N, Rao AS, Nalesnik MA, Watkins SC, DeLeo A, Trucco M, et al: A fresh look at augmenter of liver regeneration in rats. Hepatology 29: 1435-1445, 1999.
10. Fass D: The Erf family of sulphhydroxyl oxidases. Biochim Biophys Acta 1783: 557-566, 2008.
11. Jung YS, Kim SJ, Kwon DY, Jun DS and Kim YC: Significance of alterations in the metabolomics of sulfur-containing amino acids during liver regeneration. Biochimie 95: 1605-1610, 2013.
12. Ferecatu I, Goncalves S, Golinklini-Cohen MP, Clemanney M, Martelli I, Riquier S, Guittet E, Latour JM, Puccio H, Drapier JC, et al: The diabetes drug target MitoNEET governs a novel trafficking pathway to rebuild an Fe-S cluster into cytosolic aconitase/iron regulatory protein 1. J Biol Chem 289: 28070-28086, 2014.
13. Todd LR, Damin MN, Gomathinayagam R, Horn SR, Means AR and Sankar U: Growth factor erl-1 like modulates Drp1 to preserve mitochondrial dynamics and function in mouse embryonic stem cells. Mol Biol Cell 21: 1225-1236, 2010.
14. Ibrahim S and Weiss TS: Augmenter of liver regeneration: Essential for growth and beyond. Cytokine Growth Factor Rev 45: 65-80, 2019.
15. Zeng HQ, Luo Y, Lou SF, Liu Q, Zhang L and Deng JC: Silencing of augmenter of liver regeneration inhibited cell proliferation and triggered apoptosis in U266 human multiple myeloma cells. Braz J Med Biol Res 50: e6139, 2017.
16. Kim HY, Stojadinovic A and Izadjoo MJ: Immunization, hybridoma generation, and selection for monoclonal antibody production. Methods Mol Biol 1131: 33-45, 2014.
17. Anders S and Huber W: Differential expression analysis for sequence count data. Genome Biol 11: R106, 2010.
18. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, Lin J, Munguez P, Bork P, von Mering C, et al: STRING v9.1: Protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 41D: D808-D815, 2013.
19. Chin CH, Chen SH, Wu HH, Ho CW, Ko MT and Lin CY: cytoHubba: Identifying hub objects and sub-networks from complex interactome. BMC Syst Biol 8 (Suppl 4): S11, 2014.
20. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta CT) Method. Methods 25: 402-408, 2001.
21. Vodovozov Y, Prelich J, Lagoa C, Barclay D, Zamora R, Murase N and Gandhi CR: Augmenter of liver regeneration (ALR) is a novel biomarker of hepatocellular stress/inflammation: In vitro, in vivo and in silico studies, Mol Med 18: 1421-1429, 2013.
22. Cao Y, Fu YL, Yu M, Yue PB, Ge CH, Xu WX, Zhan YQ, Li CY, Li W and Wang XH: Human augmenter of liver regeneration is essential for hepatoma cell viability and resistance to radiation-induced oxidative stress. Free Radic Biol Med 47: 1057-1066, 2009.
23. Kanelhisa M, Furumichi M, Tanabe M, Sato Y and Morishima K: KEGG: New perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res 45D: D353-D361, 2017.
24. Sun Y, Liu WZ, Liu T, Feng X, Yang N and Zhou HF: Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J Recept Signal Transduct Res 35: 600-604, 2015.
25. Giordano R, Hagtya M, Seki T, Shimonishi M, Sakai H, Michaelson J, Francavilla A, Starzl TE and Trucco M: Analysis of the structure and expression of the augmenter of liver regeneration (ALR) gene. Mol Med 2: 97-108, 1996.
26. Hu Y, Xiang DR, Huang HJ, Li J and Sheng JF: Expression level of augmenter of liver regeneration in patients with hepatic failure and hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 9: 492-498, 2010.
27. Gatzidou E, Mantzourani M, Giaginis C, Giagini A, Patsouris E, Kouraklis G and Theocaris S: Augmenter of liver regeneration gene expression in human colon cancer cell lines and clinical tissue samples. J BUON 20: 84-91, 2015.

28. Shen Y, Liu Q, Sun H, Li X, Wang N and Guo H: Protective effect of augmenter of liver regeneration on vincristine-induced cell death in Jurkat T leukemia cells. Int Immunopharmacol 17: 162-167, 2013.

29. Polimeno L, Pesetti B, Lisowsky T, Iannone F, Resta L, Giorgio F, Mallamaci R, Buttiglione M, Santovito D, Vitiello F, et al: Protective effect of augmenter of liver regeneration on hydrogen peroxide-induced apoptosis in SH-SY5Y human neuroblastoma cells. Free Radic Res 43: 865-875, 2009.

30. Polimeno L, Pesetti B, De Santis F, Resta L, Rossi R, De Palma A, Girardi B, Amoruso A and Francavilla A: Decreased expression of the augmenter of liver regeneration results in increased apoptosis and oxidative damage in human-derived glioma cells. Cell Death Dis 3: e289, 2012.

31. Zhang LM, Liu DW, Liu JB, Zhang XL, Wang XB, Tang LM and Wang LQ: Effect of naked eukaryotic expression plasmid encoding rat augmenter of liver regeneration on acute hepatic injury and hepatic failure in rats. World J Gastroenterol 11: 3680-3685, 2005.

32. Ilowski M, Kleespies A, de Toni EN, Donabauer B, Jauch KW, Hengstler JG and Thasler WE: Augmenter of liver regeneration (ALR) protects human hepatocytes against apoptosis. Biochem Biophys Res Commun 404: 148-152, 2011.

33. Dayoub R, Thasler WE, Bosserhoff AK, Singer T, Jauch KW, Schlitt HJ and Weiss TS: Regulation of polyamine synthesis in human hepatocytes by hepatotropic factor augmenter of liver regeneration. Biochem Biophys Res Commun 345: 181-187, 2006.

34. Polimeno L, Pesetti B, Annnoscia E, Giorgio F, Francavilla R, Lisowsky T, Gentile A, Rossi R, Bucci A and Francavilla A: Alrp, a survival factor that controls the apoptotic process of regenerating liver after partial hepatectomy in rats. Free Radic Res 45: 534-549, 2011.

35. Liao XH, Zhang L, Liu Q, Sun H, Peng CM and Guo H: Augmenter of liver regeneration protects kidneys from ischaemia/reperfusion injury in rats. Nephrol Dial Transplant 25: 2921-2929, 2010.

36. Liao XH, Chen GT, Li Y, Zhang L, Liu Q, Sun H and Guo H: Augmenter of liver regeneration attenuates tubular cell apoptosis in acute kidney injury in rats: The possible mechanisms. Ren Fail 34: 590-599, 2012.

37. Wang N, Sun H, Shen Y, Li XF, Pan T, Liu GL and Liu Q: Augmenter of liver regeneration inhibits apoptosis of activated human peripheral blood lymphocytes in vitro. Immunopharmacol Immunotoxicol 35: 257-263, 2013.

38. Francavilla A, Vujanovic NL, Polimeno L, Azzarone A, Iacobellis A, Deleo A, Hagiya M, Whiteside TL and Starzl TE: The in vivo effect of hepatotropic factors augmenter of liver regeneration, hepatocyte growth factor, and insulin-like growth factor-II on liver natural killer cell functions. Hepatology 25: 411-415, 1997.

39. Weiss TS, Lupke M, Ibrahim S, Buechler C, Lorenz J, Rueemmele P, Hofmann U, Melter M and Dayoub R: Attenuated lipotoxicity and apoptosis is linked to exogenous and endogenous augmenter of liver regeneration by different pathways. Plos One 12: e0184282, 2017.

40. Huang TC, Chiu PR, Chang WT, Hsieh BS, Huang YC, Cheng HL, Huang LW, Hu YC and Chang KL: Epirubicin induces apoptosis in osteoblasts through death-receptor and mitochondrial pathways. Apoptosis 23: 226-236, 2018.

41. Li Y, Li M, Xing G, Hu Z, Wang Q, Dong C, Wei H, Fan G, Chen J, Yang X, et al: Stimulation of the mitogen-activated protein kinase cascade and tyrosine phosphorylation of the epidermal growth factor receptor by hepatopoietin. J Biol Chem 275: 37443-37447, 2000.

42. Zhu J, Bing C and Wilding JP: Ix,25(OH)2D3 attenuates IL-6 and IL-1β-mediated inflammatory responses in macrophage conditioned medium-stimulated human white preadipocytes by modulating p44/42 MAPK and NF-kB signaling pathways. Diabetol Metab Syndr 11: 9, 2019.

43. Yu Y, Wei SG, Zhang ZH, Weiss RM and Felder RB: ERK1/2 MAPK signaling in hypothalamic paraventricular nucleus contributes to sympathetic excitation in rats with heart failure after myocardial infarction. Am J Physiol Heart Circ Physiol 310: H732-H739, 2016.

44. von Kriesheim A, Baiocchi D, Birtwistle M, Sumpton D, Bienvenut W, Morrice N, Yamada K, Lamond A, Kalna G, Orton R, et al: Cell fate decisions are specified by the dynamic ERK interactome. Nat Cell Biol 11: 1458-1464, 2009.

45. Sławińska-Brych A, Zdzińska B, Czerwonka A, Mizerska-Kowalska M, Dmoszyńska-Graniczka M, Stepulak A and Gagoś M: Xanthohumol exhibits anti-myeloma activity in vitro through inhibition of cell proliferation, induction of apoptosis via the ERK and JNK-dependent mechanism, and suppression of sIL-6R and VEGF production. Biochim Biophys Acta, Gen Subj 1863: 129408: 2019.

46. Park S, Lee HJ, Jeong SJ, Song HS, Kim M, Lee HJ, Lee EO, Kim DH, Ahn KS and Kim SH: Inhibition of Jak1/Stat3 signaling mediates compound K-induced apoptosis in human multiple myeloma U266 cells. Food Chem Toxicol 49: 1367-1372, 2011.

47. Dayoub R, Buerger L, Ibrahim S, Melter M and Weiss TS: Augmenter of liver regeneration (ALR) exhibits a dual signaling impact on hepatic acute-phase response. Exp Mol Pathol 102: 428-433, 2017.

48. Teng EC, Todd LR, Ribar TJ, Lento W, Dimascio L, Means AR and Sankar U: Gfer inhibits Jab1-mediated degradation of p27kip1 to restrict proliferation of hematopoietic stem cells. Mol Biol Cell 22: 1312-1320, 2011.

49. Yang J, Chen L, Yan Y, Qiu J, Chen J, Song J, Rao Q, Ben-David Y, Li Y and Hao X: BW18, a C-21 steroidal glycoside, exerts an effect of augmenter of liver regeneration on vincristine-induced apoptosis and oxidative damage in human‑derived glioma cells. Cell Death Dis 3: e289, 2012.

50. Huang TC, Chiu PR, Chang WT, Hsieh BS, Huang YC, Cheng HL, Huang LW, Hu YC and Chang KL: Epirubicin induces apoptosis in osteoblasts through death-receptor and mitochondrial pathways. Apoptosis 23: 226-236, 2018.